Merck Announces €59 Million Antibody-Drug Conjugate Manufacturing Expansion


Merck has announced a €59 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin, USA. This investment will allow large-scale manufacturing of increasingly potent compounds for therapies that have the potential to treat cancer. Completion is expected by mid-2022 and should add approximately 50 full-time jobs starting in 2021.


“ADCs have posted incredible growth over the last decade, and regulatory agencies’ approval in recent years demonstrate their promise as a targeted therapy,” said Andrew Bulpin, head of Process Solutions, Life Science, at Merck. “With more than 35 years of experience in this space, we have been a frontrunner in the development and manufacturing of biologics, conjugation processes and small molecules. This investment underscores our commitment to working with innovators to bring new treatments to patients quickly and more effi ciently.”


Merck’s new 6,500 m2 commercial building will be one of the largest dedicated HPAPI manufacturing facilities specifi cally designed to handle single-digit nanogram occupational exposure limit materials. The project is an addition to the company’s Madison campus, which was the fi rst commercial ADC facility in North America designed to handle highly active materials. The new building will join Merck’s established campus in St Louis, Missouri, USA, which specialises in ADC bio-conjugation, active pharmaceutical ingredients, excipient and adjuvants manufacturing.


More information online: ilmt.co/PL/QLze 53196pr@reply-direct.com


CEO to Steer Growth in iPSC Markets


Liam Taylor has been appointed CEO of Axol Bioscience, a developer of stem cell technology and cell-based assay systems for drug discovery, with a focus on maximizing team potential and the company’s iPSC (induced pluripotent stem cell) technologies, products and services.


Liam is a highly experienced senior executive with extensive knowledge of running commercial, operations, fi nance and innovation teams in the diagnostic, pharma and life science sector, both in the UK and US. Most recently he was CFO and then Managing Director of BBI Solutions, during which time the business’ annual revenues grew from £23 million to over £52 million, driven by organic growth and strategic acquisitions, which broadened the Company’s product and service offerings.


Dr Jonathan Milner, Chairman, Axol Bioscience, said: “The Board is delighted to appoint Liam as Axol’s new CEO. His wealth of experience and comprehensive knowledge of the pharma and life science sector will be invaluable in unlocking the full potential of the Company.”


“The progress achieved at Axol Bioscience in developing high quality and consistent iPSCs has been impressive, and I am excited to be joining at an exciting point in the Company’s development where we will be working to scale up operations to support the rapidly growing biotech and pharmaceutical markets, to support increases in effi ciency within drug screening and discovery,” Mr Taylor added.


More information online: ilmt.co/PL/VkRy 53444pr@reply-direct.com


PRISYM ID Announces New Senior Appointment to Drive Further Growth in Clinical Trials Arena


PRISYM ID, a leading provider of regulated content and label management solutions, has announced the appointment of Robert Bowdish as Director of Clinical Trials Sales for North America.


Robert has wide-ranging healthcare industry sales experience. Having started out working as a pharmaceutical sales representative 26 years ago, he has been specialising in the regulatory and clinical software solutions and services market for the past decade.


He has joined PRISYM ID from Parexel Informatics, where he was initially appointed Senior Director for Solutions Consulting and then became Senior Director for Regulatory Clinical Solutions, Global Sales, where he led a team of sales directors working across diverse sectors.


Prior to that, he worked as a Senior Account Executive for Truven Health Analytics, which was acquired by IBM Watson Health.


Other posts that Robert has held include Regional Sales Director for Takeda Pharmaceuticals in North America, leading a commercial team of 10 district managers and 100 sales representatives.


Warren Stacey, SVP of Sales at PRISYM ID, commented: “Robert Bowdish is a fantastic addition to our team at PRISYM ID. He will take the lead driving Clinical Trials Sales in the North American market, building on his relationships with pharma and CROs, demonstrating how our market-leading products can be integrated into a clinical trial supply chain to deliver a compliant labelling solution.”


Robert Bowdish


More information online: ilmt.co/PL/qga5 53127pr@reply-direct.com


AMETEK Land Announces High-temperature Infrared Calibration and Service Centre in the Gulf Cooperation Council


In partnership with AIMS (Analytical Instrumentation & Maintenance Systems), the AMETEK Land Middle East Service Centre, based in Abu Dhabi, offers inspection, calibration, certifi cation, and repair of all manufacturers’ infrared pyrometers, scanners, and thermal imagers. It uses standards traceable to the AMETEK Land laboratory in the United Kingdom, which is accredited to the international standard ISO / IEC 17025:2017 (general requirements for the competence of testing and calibration laboratories), to offer a comprehensive preventative maintenance and calibration service.


l-r Prasath Venkatasamy, Regional Manager, Business Development & Service Middle East & India and Ambrish Salakki, Product Engineer, AIMS.


AMETEK Land, a world leader in non-contact temperature measurement and combustion and emissions monitoring equipment, has opened a high-temperature infrared calibration and service centre in the Gulf Cooperation Council (GCC), adding to its expansive global service centre network.


“We are delighted to open a new service centre, which will enable us to extend our services to companies across the whole of the Middle East,” explained Prasath Venkatasamy, Regional Business Development and Service Manager for AMETEK Land. “We see major growth potential from industrial companies in the GCC that are looking to maintain the highest accuracy of their instruments to optimise quality and production. Our calibration services verify the performance accuracy of an instrument at a given point in time by quantifying its errors, which are reported in a calibration certifi cate.”


“The establishment of an AIMS and AMETEK Land calibration and repair centre for infrared instrumentation in Abu Dhabi further


solidifi es our commitment to the In-Country Value (ICV) program to grow and diversify the UAE economy and create job opportunities in the UAE. The ICV program is fully integrated into our business processes, procedures, and initiatives. We very much look forward to joint success with this new venture,” commented Zaheer Juddy, Managing Director at AIMS.


The calibration of instruments is essential to improve practical temperature measurement performance. The service centre provides calibration across an extensive temperature range, from 50°C to 1600°C, for AMETEK Land and other manufacturers’ instrumentation. With repeated calibrations, a history of instrument stability can be built, providing a useful insight into long term performance.


At its new Middle Eastern facility, AMETEK Land will provide a full-service offering that encompasses inspection, calibration, certifi cation, and repair of infrared temperature measurement instruments and will be operated by fully trained technicians using approved and traceable certifi cation equipment.


More information online: ilmt.co/PL/ZXxl 53225pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76